Literature DB >> 19268309

The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.

Eniko Vamos1, Arpad Pardutz, Peter Klivenyi, Jozsef Toldi, Laszlo Vecsei.   

Abstract

The metabolism of tryptophan mostly proceeds through the kynurenine pathway. The biochemical reaction includes both an agonist (quinolinic acid) at the N-methyl-d-aspartate receptor and an antagonist (kynurenic acid). Besides the N-methyl-d-aspartate antagonism, an important feature of kynurenic acid is the blockade of the alpha7-nicotinic acetylcholine receptor and its influence on the alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptor. Kynurenic acid has proven to be neuroprotective in several experimental settings. On the other hand, quinolinic acid is a potent neurotoxin with an additional and marked free radical-producing property. In consequence of these various receptor activities, the possible roles of these substances in various neurological disorders have been proposed. Moreover, the possibility of influencing the kynurenine pathway to reduce quinolinic acid and increase the level of kynurenic acid in the brain offers a new target for drug action designed to change the balance, decreasing excitotoxins and enhancing neuroprotectants. This review surveys both the early and the current research in this field, focusing on the possible therapeutic effects of kynurenines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19268309     DOI: 10.1016/j.jns.2009.02.326

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  43 in total

1.  Duplication 16p11.2 in a child with infantile seizure disorder.

Authors:  Jirair K Bedoyan; Ravinesh A Kumar; Jyotsna Sudi; Faye Silverstein; Todd Ackley; Ramaswamy K Iyer; Susan L Christian; Donna M Martin
Journal:  Am J Med Genet A       Date:  2010-06       Impact factor: 2.802

2.  Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior.

Authors:  Michelle C Potter; Greg I Elmer; Richard Bergeron; Edson X Albuquerque; Paolo Guidetti; Hui-Qiu Wu; Robert Schwarcz
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

3.  Behavioural studies with a newly developed neuroprotective KYNA-amide.

Authors:  Levente Gellért; Dániel Varga; Marian Ruszka; József Toldi; Tamás Farkas; István Szatmári; Ferenc Fülöp; László Vécsei; Zsolt Kis
Journal:  J Neural Transm (Vienna)       Date:  2011-08-05       Impact factor: 3.575

Review 4.  Structure, expression, and function of kynurenine aminotransferases in human and rodent brains.

Authors:  Qian Han; Tao Cai; Danilo A Tagle; Jianyong Li
Journal:  Cell Mol Life Sci       Date:  2009-10-15       Impact factor: 9.261

5.  Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72).

Authors:  M Lukács; K Warfvinge; J Tajti; F Fülöp; J Toldi; L Vécsei; L Edvinsson
Journal:  J Headache Pain       Date:  2017-03-23       Impact factor: 7.277

6.  Gas chromatography/tandem mass spectrometry detection of extracellular kynurenine and related metabolites in normal and lesioned rat brain.

Authors:  Francesca M Notarangelo; Hui-Qiu Wu; Anthony Macherone; David R Graham; Robert Schwarcz
Journal:  Anal Biochem       Date:  2011-12-28       Impact factor: 3.365

7.  A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study : special issue related to kynurenine.

Authors:  Ildikó Demeter; Károly Nagy; Levente Gellért; László Vécsei; Ferenc Fülöp; József Toldi
Journal:  J Neural Transm (Vienna)       Date:  2012-01-10       Impact factor: 3.575

8.  Branched-chain amino acids alter neurobehavioral function in rats.

Authors:  Anna Coppola; Brett R Wenner; Olga Ilkayeva; Robert D Stevens; Mauro Maggioni; Theodore A Slotkin; Edward D Levin; Christopher B Newgard
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-12-18       Impact factor: 4.310

9.  ONO-2506 inhibits spike-wave discharges in a genetic animal model without affecting traditional convulsive tests via gliotransmission regulation.

Authors:  Satoshi Yamamura; Masamitsu Hoshikawa; Kato Dai; Hiromitsu Saito; Noboru Suzuki; Osamu Niwa; Motohiro Okada
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 10.  The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia.

Authors:  María Isabel Cuartero; Juan de la Parra; Alicia García-Culebras; Iván Ballesteros; Ignacio Lizasoain; María Ángeles Moro
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.